Drug compliance in therapeutic trials: A review

Controlled Clinical Trials

Volumn 19, Issue 3, 1998, Pages 257-268

  Boudes, Pol ^a,b  

^a Searle European Clinical R and D   (France)

^b Wyeth Ayerst Research European CR and D Department   (France)

Author keywords

Clinical trials; Compliance; Drug development

Indexed keywords

CLINICAL PRACTICE; DATA ANALYSIS; DRUG SCREENING; PATIENT COMPLIANCE; PUBLICATION; REVIEW;

CLINICAL TRIALS; DATA INTERPRETATION, STATISTICAL; HUMANS; PATIENT COMPLIANCE;

EID: 0031781265     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(98)00005-1     Document Type: Article

References (75)

1. Wright EC. Non-compliance - or how many aunts has Mathilda? Lancet 1993; 342:909-913.
2. Sclar DA. Improving medication compliance: a review of selected issues. Clin Ther 1991;13:436-440.
3. Richardson JL, Shetton DR, Krailo M, et al. The effect of compliance with treatment on survival among patients with hematologic malignancies. J Clin Oncol 1990;8:356-364.
4. Vander Stichele R. Measurement of patient compliance and the interpretation of randomised clinical trials. Eur J Clin Pharmacol 1991;41:27-35.
5. Haynes RB, Dantes R. Patient compliance and the conduct and interpretation of therapeutic trials. Controlled Clin Trials 1987;8:12-19.
6. Epstein LH. The direct effects of compliance on health outcome. Health Psychol 1984;3:385-393.
7. Spilker B. Methods of assessing and improving patient compliance in clinical trials. In: Spilker B, ed. Guide to Clinical Trials. New York: Raven Press; 1991:102-114.
8. Haynes RB, Dantes R. Determinants of compliance: the disease and the mechanics of treatment. In: Haynes RB, Taylor DW, Sackett DL, eds. Compliance in Health Care. Baltimore: John Hopkins University Press; 1979:49-62.
9. Stephenson BJ, Rowe BH, Haynes RB, et al. Is this patient taking the treatment as prescribed? JAMA 1993;269:2779-2781.
10. Coons SJ, Sheahan SL, Martin SS, et al. Predictors of medication noncompliance in a sample of older adults. Clin Ther 1994;16:110-117.
11. Samet JH, Libman H, Steger KA, et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med 1992;92:495-502.
12. Rudd P, Lenert L. Pharmacokinetics as an aid to optimising compliance with medications. Clin Pharmacokinet 1995;28:1-6.
13. Larsen GL. Asthma in children. N Engl J Med 1992:326:1540-1545.
14. Catalona WJ. Management of cancer of the prostate. N Engl J Med 1994;331:996-1004.
15. Farmer KC, Jacobs EW, Phillips CR. Long-term patient compliance with prescribed regimens of calcium channel blockers. Clin Ther 1994;16:316-326.
16. Boudes P. Good clinical practice in internal medicine. Ann Med Intern 1991; 142: 435-438.
17. Asplund J, Danielson M, Ohman P. Patients' compliance in hypertension: the importance of numbers of tablets. Br J Clin Pharmacol 1984;17:547-552.
18. Wilde MI, Langtry HD. Zidovudine: an update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1993;46:515-578.
19. Rudd P, Byyny RL, Zachary V, et al. The natural history of medication compliance in a drug trial: limitations of pill counts. Clin Pharmacol Ther 1989;46:169-176.
20. Temple R. Trends in pharmaceutical development. Drug Inf J 1993;27:355-366.
21. Haynes RB, Taylor DW, Sackett DL, et al. Can simple clinical measurements detect patients' noncompliance? Hypertension 1980;2:757-764.
22. Compliance of patients currently on study. In: Iber FL, Riley WA, Murray PJ, eds. Conducting Clinical Trials. New York: Plenum Medical Book Company; 1987.
23. Approaches to improving adherence to antituberculosis therapy. JAMA 1993; 269:1096-1098.
24. Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment of tuberculosis: we can't afford not to try it. N Engl J Med 1993;328:576-578.
25. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse of tuberculosis. N Engl J Med 1994;330:1179-1184.
26. Urquhart J. Role of patient compliance in clinical pharmacokinetics: a review of recent research. Clin Pharmacokinet 1994;27:202-215.
27. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984;6:592-599.
28. Pullar T, Feely MP. Reporting compliance in clinical trials. Lancet 1990;336:1252-1253.
29. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:3273-3277.
30. Cramer JA. Microelectronic systems for monitoring and enhancing patient compliance with medication regimens. Drugs 1995;49:321-327.
31. Averbuch M, Weintraub M, Pollack DJ. Compliance assessment in clinical trials: the MEMs device. J Clin Res Pharmacoepidemiol 1990;4:199-204.
32. Feinstein AR. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med 1990;150:1377-1378.
33. Aronson JK, Hardman M. Why monitor drug therapy? Br Med J 1992;305:947-948.
34. Bolla G, Disdier P, Roux F, et al. Observance des inhibiteurs de l'enzyme de conversion de l'angiotensine. Presse Med 1994;23:491.
35. Richardson D, Liou SH, Kahn JO. Uric acid and didanosine compliance in AIDS clinical trials: an analysis of AIDS Clinical Trials Group protocol 116A and 116B/ 117. J Acquir Immune Defic Syndr 1993;6:1212-1223.
36. Lim LL. Estimating compliance to study medication from serum drug levels: application to an AIDS clinical trial of zidovudine. Biometrics 1992;48:619-630.
37. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994;343:871-881.
38. Thompson WL. Clinical pharmacology of a marker of a patient compulsiveness. Controlled Clin Trials 1984;5(suppl 4):522-525.
39. Deuschle K, Jordhal C, Hobby G. Clinical usefulness of riboflavin-tagged isoniazid for self-medication in tuberculosis patients. Am Rev Respir Dis 1960;82:1-10.
40. Pullar T, Birtwell AJ, Wiles PG, et al. Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily. Clin Pharmacol Ther 1988;44:540-545.
41. Wolff K, Hay A, Raistrick D, et al. Measuring compliance in methadone maintenance patients: use of a pharmacologic indicator to estimate methadone plasma levels. Clin Pharmacol Ther 1991;50:199-207.
42. Mäenpää H, Javela K, Pikkarainen J, et al. Minimal doses of digoxin: a new marker for compliance to medication. Eur Heart J 1987;8(suppl 1):31-37.
43. Lieberman R, Katzper M, Peck CC. Pharmacokinetics compartmental (COM) modeling and dose (D) regimen (REG) analysis for concentration controlled trials (CCT) of suramin in cancer (CA) using difference equation simulation (DES). Clin Pharm Ther 1991;49:123.
44. Flexner C, Van der Horst C, Jacobson MA, et al. Relationship between plasma concentration of 3′-deoxy-3′-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials. J Inf Dis 1994;170:1394-1403.
45. Sale ME, Blaschke TF. Incorporating pharmacokinetic/pharmacodynamic modeling in drug development: are we ready? Drug Inf J 1992;26:119-124.
46. Walker R. Which medication compliance device? Pharm J 1992;249:605-607.
47. Rudd P. Medication packaging as a simple solution to non-adherence problems. Clin Pharmacol Ther 1979;25:247.
48. Walker R. Stability of medicinal products in compliance devices. Pharm J 1992;248:124-126.
49. Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalvirus retinitis in patients with AIDS. N Engl J Med 1995;333:615-620.
50. Collier A, Coombs R, Timpone J, et al. Comparative study of Ro 31-8959 and zidovudine (ZDV) vs ZDV and zalcitabine (ddC) vs Ro-31-8959, ZDV, and ddC. Yokohama, Japan: Tenth International Conference on AIDS; 1994:058B.
51. Cockburn J, Gibberd RW, Ried AL, et al. Determinants of non-compliance with short-term antibiotic regimens. Br Med J 1987;295:814-818.
52. Macharia WM, Leon G, Rowe BH, et al. An overview of interventions to improve compliance with appointment-keeping for medical services. JAMA 1992;267: 1813-1817.
53. Waldron HA, Cookson RF. Avoiding the pitfalls of sponsored multicentre research in general practice. Br Med J 1993;307:1331-1334.
54. Blackwell B. Drug therapy: patient compliance. N Engl J Med 1973;289:249-252.
55. Haynes RB, Gibson ES, Taylor DW, et al. Process versus outcome in hypertension: a positive result. Circulation 1982;65:28-33.
56. Markowitz M. Eradication of rheumatic fever: an unfulfilled hope. Circulation 1970;41:1077-1084.
57. Stewart M. The validity of an interview to assess a patient's drug taking. Am J Prev Med 1987;3:95-100.
58. Geletko S, Jones K, Fiore T, et al. Electronic monitoring of medication compliance in AIDS patients: importance in the assessment of fluconazole porphylaxis in high-risk women [abstract]. ICAAC 1992 #1084.
59. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chron Dis 1967:20:637-648.
60. Lee YJ, Ellenberg JH, Hirtz DG, et al. Analysis of clinical trials by treatment actually received: is it really an option? Stat Med 1991;10:1595-1605.
61. Pledger GW. Compliance in clinical trials: impact on design, analysis, and interpretation. In: Schmidt D, Leppick IE, eds. Compliance in Epilepsy. Amsterdam: Elsevier, 1988.
62. Goldsmith CH. The effect of compliance distributions on therapeutic trials. In: Haynes RB, Taylor DW, Sackett DL, eds. Compliance in Health Care. Baltimore: John Hopkins University Press; 1979.
63. Lakatos E. Sample size determination in clinical trials with time-dependent rates of losses and non-compliance. Controlled Clin Trial 1986;7:189-199.
64. Sullivan SD, Kreling DH. Noncompliance with medication regimens and subsequent hospitalisations: a literature analysis and cost of hospitalisation estimate. J Res Pharm Econ 1990;2:19-33.
65. Clinical epidemiology. In: Feinstein AR, ed. The Architecture of Clinical Research. Philadelphia: WB Saunders; 1985.
66. Epstein LH, Cluss PA. A behavioural medicine perspective on adherence to long-term medical regimens. J Consult Clin Psychol 1982;50:950-971.
67. Sackett DL, Haynes RB, Gibson ES, et al. The problem of compliance with antihypertensive therapy. Prac Cardiol 1976;2:35-39.
68. Smith M. The cost of noncompliance and the capacity of improved compliance to reduce health care cost. In: Improving Medication Compliance: Proceedings of a Symposium. Reston, VA: National Pharmaceutical Council; 1984:35-44.
69. Kessler DA, Rose JL, Temple RJ, et al. Therapeutic-class wars: drug promotion in a competitive marketplace. N Engl J Med 1994;331:1350-1353.
70. Getting Your Drug Approved: FDA's Own Guideline 2d ed. Arlington, VA: Washington Business Information; 1990.
71. Instructions for authors. JAMA 1993;270:33-36.
72. Instructions to authors. Br Med J 1995;310:50-53.
73. Instructions for authors. Ann Intern Med 1994;121:14-17.
74. Goodman SN, Berlin J, Fletcher SW, et al. Manuscript quality before and after peer review and editing at Annals of Internal Medicine. Ann Intern Med 1994;121:11-21.
75. Bergmann JF, Chassany O, Segrestaa JM, et al. Examen critique des grilles de lecture des essais thérapeutiques. Thérapie 1994:49:181-184.